Danaher announced the completion of its acquisition of Masimo Corporation, adding the pulse oximetry and patient monitoring specialist to its Diagnostics segment and strengthening its capabilities in acute care settings.
Masimo’s advanced sensor technology and AI-enabled patient monitoring solutions complement Danaher’s diagnostics portfolio. Following the transaction, Masimo has become a wholly owned subsidiary of Danaher and its shares have ceased trading on the Nasdaq Stock Market. The company will continue to operate under the Masimo brand as a standalone operating company within Danaher’s Diagnostics segment.
Danaher said there is no change to its previously issued second-quarter and full-year 2026 guidance excluding Masimo’s contribution. The company expects Masimo to have an immaterial impact on second-quarter results and plans to update its full-year outlook when it reports second-quarter earnings.
Danaher, which employs approximately 60,000 associates worldwide, said the acquisition is expected to enhance its ability to deliver differentiated products in acute care settings while accelerating Masimo’s growth and expanding its global reach.
KEY QUOTES:
“Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo’s growth and global reach. We are excited to welcome the Masimo team to Danaher.”
Julie Sawyer Montgomery, Executive Vice President of Diagnostics, Danaher
